JAZZ - Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results
The biggest news for Jazz Pharmaceuticals (NASDAQ: JAZZ) in recent months was the company's announcement earlier this month that it plans to acquire GW Pharmaceuticals in a $7.6 billion deal. Investors initially weren't very thrilled with the acquisition, but later seemed to view it in a more positive light.
Now, Jazz has more news that investors eagerly awaited. The drugmaker announced its fourth-quarter results after the market closed on Tuesday. Here are the highlights from Jazz's Q4 update.
Image source: Getty Images.
For further details see:
Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results